Baili Tianheng (02615.HK) said its in-house bispecific ADC iza-bren (BL-B01D1) has had a marketing application for triple-negative breast cancer accepted by the National Medical Products Administration’s Center for Drug Evaluation. The filing covers treatment of unresectable locally advanced or metastatic TNBC in patients who progressed on prior taxane therapy. This is the drug’s third MAA acceptance by the CDE, after submissions for nasopharyngeal carcinoma and esophageal squamous cell carcinom

Baili Tianheng (02615.HK) said its in-house bispecific ADC iza-bren (BL-B01D1) has had a marketing application for triple-negative breast cancer accepted by the National Medical Products Administration’s Center for Drug Evaluation. The filing covers treatment of unresectable locally advanced or metastatic TNBC in patients who progressed on prior taxane therapy. This is the drug’s third MAA acceptance by the CDE, after submissions for nasopharyngeal carcinoma and esophageal squamous cell carcinoma.